Neos Therapeutics Inc., of Grand Prairie, Texas, in a regulatory filing with the SEC disclosed that it entered a first amendment to an existing facility agreement with Deerfield Private Design Fund III LP and Deerfield Special Situations Fund LP, who provided $60 million in May last year.